Blue Matter Launches Behavioral Science Center of Excellence to Strengthen Biopharma Market Research and Decision-Making
Blue Matter has announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the company’s Blue Matter Insights primary market research team designed to help biopharmaceutical companies better understand the factors influencing healthcare decisions. The new center will apply behavioral science principles to examine the motivations, perceptions, emotions, biases, and contextual influences that shape decisions made by healthcare professionals, patients, care partners, and other stakeholders across the healthcare ecosystem.
The launch formalizes Blue Matter’s existing expertise in behavioral science and establishes a dedicated capability to integrate behavioral frameworks more systematically into primary market research and data analytics. Through this initiative, the company aims to help biopharmaceutical organizations move beyond what stakeholders report in interviews and surveys to understand why they make particular decisions in real-world healthcare settings.
For pharmaceutical and biotechnology companies, understanding stakeholder behavior is essential to developing effective product positioning, planning commercial launches, evaluating market opportunities, and making strategic decisions throughout a product’s lifecycle. While conventional market research can provide valuable information about customer preferences, treatment priorities, and prescribing intentions, reported attitudes do not always translate directly into actual behavior.
Blue Matter’s new Center of Excellence is intended to address this challenge by applying evidence-based behavioral science frameworks to research programs and translating the resulting insights into practical recommendations for medical, market access, new product planning, and commercial teams.
The initiative will serve organizations across the biopharmaceutical industry, including established global companies and emerging innovators. By combining academic expertise, applied industry experience, and integrated research capabilities, the BeSci CoE will seek to provide a more comprehensive understanding of the factors influencing healthcare decisions and the ways these factors may change over time.
Addressing the Gap Between Reported Preferences and Real-World Behavior
A central objective of the Behavioral Science Center of Excellence is to investigate the difference between what healthcare stakeholders say they will do and what they actually do in practice. This discrepancy, often described as the “say-do” gap, presents a significant challenge for biopharmaceutical companies seeking to understand treatment decisions and anticipate market behavior.
Traditional market research methods, including surveys and interviews, are widely used to assess healthcare professionals’ treatment preferences, patients’ experiences, and stakeholder perceptions of medicines. These approaches can help researchers identify stated priorities, compare preferences across groups, and evaluate responses to potential product attributes or clinical evidence.
However, decisions in healthcare are influenced by factors that respondents may not fully recognize or articulate. Physicians may identify clinical efficacy as their primary treatment consideration, for example, while their actual prescribing behavior may also be influenced by familiarity with a therapy, established clinical routines, perceived treatment risks, patient expectations, institutional protocols, or practical barriers to prescribing.
Similarly, patients may express a willingness to begin a treatment but hesitate when faced with concerns about adverse effects, administration requirements, treatment costs, or changes to their daily routines. Care partners may also influence treatment decisions through their understanding of a condition, perceptions of treatment burden, and expectations about patient outcomes.
Behavioral science offers frameworks for examining these influences and understanding how individual decision-making interacts with the environment in which choices occur. Rather than relying exclusively on stated preferences, researchers can investigate the cognitive processes, emotional responses, social influences, and contextual conditions that may contribute to observed behavior.
Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter, emphasized the importance of understanding these underlying factors.
“You don’t need a survey to tell you that physicians see efficacy as the most important treatment decision driver,” Pilecki said. “What our clients come to us for is an understanding of why real-world prescribing often diverges from this perspective. That’s where behavioral science comes in: it gives us the best way to bridge this ‘say-do’ gap.”
His comments highlight the distinction between identifying a stated treatment priority and understanding how that priority translates into clinical practice. For biopharmaceutical organizations, this distinction can affect how market research findings are interpreted and how commercial strategies are developed.
By investigating the factors that influence actual decisions, Blue Matter’s behavioral science capability aims to help clients develop a more detailed picture of stakeholder needs, decision-making processes, and potential barriers to treatment adoption.
Integrating Behavioral Science Across Research Methods
The BeSci CoE will apply behavioral science frameworks across qualitative, quantitative, and mixed-method research. This approach is intended to help Blue Matter examine decision-making from multiple perspectives and produce findings that can support both strategic planning and operational execution.
Qualitative research can provide an in-depth understanding of how stakeholders interpret information, evaluate treatment options, and respond to different clinical or commercial circumstances. Interviews and other qualitative approaches may help researchers explore the reasoning behind decisions, identify emotional or contextual influences, and uncover factors that stakeholders do not readily express in structured questionnaires.
Quantitative research can complement these findings by measuring patterns across larger respondent groups, assessing the prevalence of particular attitudes or behaviors, and examining relationships among decision-making factors. Behavioral frameworks can help inform the questions asked, the variables assessed, and the interpretation of results.
Mixed-method research combines qualitative and quantitative approaches to provide a more comprehensive understanding of a particular market or stakeholder group. By integrating the two, researchers can explore underlying motivations in greater depth and then assess how broadly the identified patterns may apply.
Within this framework, the Center of Excellence will focus on three primary areas of work.
First, it will apply behavioral science frameworks to uncover the factors influencing provider and patient decisions. This includes examining how stakeholders process information, respond to clinical evidence, evaluate treatment alternatives, and make choices within the constraints of real-world healthcare environments.
Second, the CoE will translate behavioral insights into strategic and tactical recommendations. Research findings are intended to support decisions involving product positioning, launch planning, market access, medical strategy, and other commercial activities. The goal is to connect an understanding of stakeholder behavior with practical actions that organizations can evaluate and implement.
Third, the team will identify early signals that may indicate how stakeholder behavior and market dynamics could evolve. Changes in perceptions, decision-making patterns, treatment preferences, or contextual conditions can provide information that helps organizations assess emerging opportunities and potential challenges.
Together, these activities are intended to strengthen the connection between market research and business decision-making, helping biopharmaceutical companies interpret stakeholder behavior within the broader context of their therapeutic markets.
Supporting Medical, Market Access, and Commercial Functions
The Behavioral Science Center of Excellence is designed to support a broad range of functions within pharmaceutical and biotechnology organizations. Its intended users include medical affairs teams, market access professionals, new product planning groups, and commercial leaders.
For medical affairs teams, a deeper understanding of healthcare professionals’ decision-making processes can help clarify how physicians interpret clinical evidence, assess treatment options, and incorporate new information into practice. These insights may also help organizations identify gaps between the availability of scientific evidence and its practical application.
Market access teams face a different but related set of challenges. Treatment adoption can be influenced by reimbursement arrangements, institutional requirements, administrative processes, and perceptions of a medicine’s value. Behavioral research can help examine how these factors affect stakeholder choices and how access-related barriers interact with clinical considerations.
New product planning teams can use behavioral insights to assess potential treatment opportunities, evaluate stakeholder needs, and identify factors that may influence the acceptance of a future therapy. Understanding these influences earlier in the development and planning process may help companies evaluate different strategic scenarios before committing to major commercial decisions.
Commercial teams, meanwhile, must understand how healthcare professionals and patients perceive a product in the context of existing treatment options. Behavioral science can help researchers examine how clinical evidence, familiarity, perceived risks, patient preferences, and practical considerations contribute to treatment decisions.
The CoE is intended to serve both large biopharmaceutical companies and emerging innovators. Although these organizations may differ in scale, resources, and product portfolios, both can benefit from understanding the factors that influence stakeholder behavior and the conditions under which treatment decisions change.
The Center’s work is expected to connect research findings with the decisions these functions make throughout a product’s lifecycle, from early planning and market assessment through launch preparation and subsequent commercial strategy development.
Building on Blue Matter’s Existing Expertise
According to Blue Matter, behavioral science already informs many of the company’s existing research methodologies. The establishment of the CoE represents a formalization of that expertise rather than the introduction of an entirely separate service.
By creating a dedicated center within Blue Matter Insights, the company intends to embed behavioral science more consistently across its integrated primary market research and data analytics capabilities.
This structure is designed to bring together researchers with strong academic credentials and years of applied experience in the biopharmaceutical industry. Combining these backgrounds can help connect established behavioral science concepts with the practical challenges faced by healthcare companies operating in complex and rapidly changing markets.
The integration of behavioral science and data analytics also provides a framework for interpreting stakeholder decisions alongside broader market information. Research findings can be considered in relation to observed patterns, market dynamics, and other available evidence, helping clients develop a more complete understanding of the environments in which healthcare decisions occur.
D’Arcy King, Ph.D., Partner and Head of Primary Market Research at Blue Matter, described behavioral science as a fundamental component of the company’s research approach.
“Behavioral science isn’t a bolt-on technique for us. It is central to how we understand decision-making in complex, fast-moving markets,” King said.
She added, “By formalizing this expertise in a Center of Excellence, we are setting a higher bar for what behavioral-science-driven insights should deliver: clarity and confidence in stakeholder decision-making.”
King’s comments underscore the company’s intention to position behavioral science as an integrated capability across its research activities. The CoE is intended to establish a consistent approach to applying behavioral frameworks, interpreting findings, and translating those findings into recommendations relevant to client decisions.
Advancing Evidence-Based Insights and Industry Knowledge
In addition to its client-focused research activities, the Behavioral Science Center of Excellence will continue to contribute to broader discussions about the application of behavioral science in the biopharmaceutical sector.
Blue Matter plans to share evidence-based findings through peer-reviewed manuscripts, white papers, conference presentations, and speaker events. These activities will provide opportunities to communicate research approaches, discuss emerging insights, and contribute to industry understanding of the role behavioral science can play in healthcare decision-making.
Sharing findings through these channels can also help connect applied market research with academic and professional discussions about human behavior, decision-making, and the factors influencing healthcare choices.
The emphasis on evidence-based research reflects the importance of grounding behavioral insights in systematic investigation rather than relying solely on assumptions about why stakeholders act in particular ways. For biopharmaceutical companies, this distinction matters because commercial and medical decisions can involve substantial investments and have implications for how treatments are developed, introduced, and understood by healthcare professionals and patients.
The CoE’s planned publications and presentations will provide additional channels for communicating its work, although the company has not specified particular publication dates, upcoming conference appearances, or individual research projects associated with the launch.
Strengthening Decision-Making in a Complex Biopharma Environment
The launch of Blue Matter’s Behavioral Science Center of Excellence reflects a broader focus on understanding the human factors that influence healthcare decisions. As pharmaceutical and biotechnology markets evolve, organizations must interpret not only what stakeholders report but also the circumstances and motivations that shape their behavior.
The distinction between stated preferences and real-world actions can be particularly relevant when companies are developing positioning strategies, preparing product launches, evaluating market access challenges, or making lifecycle decisions. Behavioral science provides an additional set of research tools for examining these questions and translating findings into practical recommendations.
Through the BeSci CoE, Blue Matter aims to formalize its behavioral science expertise, integrate it across primary market research and data analytics, and support medical, market access, new product planning, and commercial functions.
By combining qualitative, quantitative, and mixed-method approaches with academic knowledge and applied biopharmaceutical experience, the company intends to help clients gain a clearer understanding of stakeholder motivations and the factors influencing treatment decisions.
The initiative also establishes a platform for sharing evidence-based findings through publications and industry events, extending the company’s work beyond individual client engagements.
While the announcement does not specify measurable performance targets or particular client outcomes for the new center, its stated objective is to improve the depth and practical relevance of market research. Ultimately, Blue Matter’s Behavioral Science Center of Excellence is designed to help biopharmaceutical organizations move beyond reported preferences toward a more comprehensive understanding of healthcare stakeholder behavior, supporting more informed decisions in increasingly complex markets.
About Blue Matter
Blue Matter (www.bluematterconsulting.com) is a global commercialization partner serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves a broad spectrum of biopharmaceutical organizations, from top-20 global companies to emerging biotech firms. Blue Matter helps clients maximize value at the product, portfolio, and organization levels by providing market insights, strategic and operational consulting, and communications services.